Major $50 Million Support for Women's Brain Health Studies at UC San Diego

It has long been known that women are nearly twice as likely as men to develop Alzheimer's disease. However, the underlying reasons for this striking difference have not yet been fully elucidated by scientists. Researchers at the University of California (UC) San Diego have launched a new and comprehensive study to fill this critical gap. A massive investment exceeding 50 million dollars, provided under the leadership of Wellcome Leap CARE and various other organizations, will accelerate research in this field. This fund will be used specifically to examine the potential effects of menopause and hormone therapy on women's dementia risk and to develop artificial intelligence-supported early diagnostic tools.

At the center of the project is Judy Pa, a Professor of Neurosciences at the UCSD School of Medicine and the Director of the Alzheimer's Disease Cooperative Study. Pa emphasizes that there is still a huge question mark in the scientific world regarding the impact of post-menopausal processes on women's cognitive health. The hormone therapy project she will lead plans to create a virtual clinical trial simulation by utilizing existing massive data sets. Thanks to this method, researchers will be able to compare the long-term health outcomes of women who start hormone therapy during menopause with those of women with similar characteristics who do not receive treatment. Our goal is to clarify which are the most appropriate and safest treatment methods for women experiencing different menopausal transitions.

This major support secured by the researchers is also a reflection of the growing interest in the field of women's health, which has been ignored and overlooked for decades. Pa notes that silence has essentially prevailed around menopause science for the last 25 years and that the topic has been neglected. The root of this silence dates back to a massive federal study published in 2002 known as the Women’s Health Initiative. The aforementioned study suggested that women using post-menopausal hormone therapy experienced higher rates of breast cancer and cardiovascular issues compared to those taking a placebo. These shocking findings completely shattered long-held beliefs that hormone therapy prevented diseases in older women, creating a profound shock in the medical world.

Following that publication in 2002, progress came to a complete halt and panic ensued in the medical community. Hormone therapies, which had been prescribed for years to prevent diseases, suddenly became associated with fear due to unexpected side effects. As Pa points out, doctors, clinics, and healthcare workers concerned about the increased risk of breast cancer in their patients almost entirely stopped prescribing hormone therapy. This abrupt shift negatively impacted all future research on women's health and hormones, setting the field back for years. Consequently, the process of studying hormones that affect women's cognitive decline suffered a major disruption.

Today, more than 20 years after those events, new data and more advanced analytical methods offer scientists the opportunity to re-evaluate this topic. Pa states that she feels fortunate to have the opportunity to work in this field and notes a reawakening of interest in menopause research within the scientific community. Next-generation data analysis techniques and the AI tools to be specifically developed hold the potential to detect Alzheimer's disease at much earlier stages. The success of this major $50 million investment will not only solve the mysteries surrounding women's brain health but will also open new horizons in the field of personalized medicine.